[badboy99]

https://en.wikipedia.org/wiki/Safinamide

Safinamide (EMD 1195686) is a candidate drug against Parkinson's disease with multiple methods of action.[1] In 2007, a Phase III clinical trial was started. It was scheduled to run until 2011.[2] The compound was originally discovered at Farmitalia-Carlo Erba and developed by Newron Pharmaceuticals, which sold the rights to Merck-Serono in 2006. In October 2011 Merck-Serono announced that they would give all rights to develop the compound back to Newron.[3]
Potential additional uses might be restless legs syndrome (RLS) and epilepsy.[4] They were being tested in Phase II trials in 2008, but no results are available.
Methods of action[edit]

Parkinson and RLS relevant mechanisms[edit]
Safinamide is a monoamine oxidase B inhibitor, reducing degradation of dopamine, and a glutamate release inhibitor.[5] It also seems to inhibit dopamine reuptake.[6] Additionally, safinamide blocks sodium and calcium channels.[5]